

Name of the Company PHARMAIDS PHARMACEUTICALS LIMITED

Statement of Profit and Loss for the Year ended 30th September, 2018

Rs. In lakhs

| | Particulars | Note No. | Qtr. Ended audited 30.09.2018 | Qtr. Ended audited 30.06.2018 | Qtr. Ended audited 30.09.2017 | Year Ended Audited 31.03.2017 | Year Ended Audited 31.03.2018 |
|------|---|----------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| I | Revenue From Operations | | - | - | 4.90 | 120.25 | 44.91 |
| II | Other Income | | 0.25 | 0.01 | 0.40 | 1.01 | 2.01 |
| III | Total Income (I+II) | | 0.25 | 0.01 | 5.30 | 121.26 | 46.92 |
| IV | EXPENSES | | | | | | |
| | Cost of materials consumed | | - | - | - | 64.49 | 3.47 |
| | Purchases of Stock-in-Trade | | - | - | 4.50 | - | 24.19 |
| | Changes in inventories of finished goods, Stock-in -Trade and work-in-progress | | - | - | (0.52) | 2.95 | 21.78 |
| | Employee benefits expense | | 1.33 | 0.86 | 1.62 | 16.63 | 6.30 |
| | Finance costs | | 0.11 | - | 0.03 | 4.01 | 0.14 |
| | Depreciation and amortization expense | | 0.02 | 0.02 | 0.02 | 6.37 | 0.11 |
| | Other expenses | | 7.84 | 2.72 | 6.88 | 70.53 | 27.79 |
| | Total expenses (IV) | | 9.30 | 3.60 | 12.53 | 164.98 | 83.77 |
| V | Profit/(loss) before exceptional items and tax (III- IV) | | (9.05) | (3.59) | (7.23) | (43.72) | (36.86) |
| VI | Exceptional Items | | - | - | - | 51.97 | - |
| VII | Profit/(loss) before tax (V+VI) | | (9.05) | (3.59) | (7.23) | 8.25 | (36.86) |
| VIII | Tax expense: | | | | | | |
| | (1) Current tax Adj. of earlier year | | - | - | 1.75 | - | 1.73 |
| | (2) Deferred tax | | - | - | - | (2.72) | (0.02) |
| IX | Profit (Loss) for the period from continuing operations (VII-VIII) | | (9.05) | (3.59) | (8.98) | 10.97 | (38.57) |
| X | Profit/(loss) from discontinued operations | | - | - | - | - | - |
| XI | Tax expense of discontinued operations | | - | - | - | - | - |
| XII | Profit/(loss) from Discontinued operations (after tax) (X-XI) | | - | - | - | - | - |
| XIII | Profit/(loss) for the period (IX+XII) | | (9.05) | (3.59) | (8.98) | 10.97 | (38.57) |
| XIV | Other Comprehensive Income | | - | - | - | - | - |
| | A (i) Items that will not be reclassified to profit or loss | | - | - | - | - | - |
| | (ii) Income tax relating to items that will not be reclassified to profit or loss | | - | - | - | - | - |
| | B (i) Items that will be reclassified to profit or loss | | - | - | - | - | - |
| | (ii) Income tax relating to items that will be reclassified to profit or loss | | - | - | - | - | - |
| XV | Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the period) | | - | - | - | - | - |
| XVI | Earnings per equity share (for continuing operation): | | - | - | - | - | - |
| | (1) Basic | | (0.27) | (0.11) | (0.26) | 0.32 | (1.13) |
| | (2) Diluted | | (0.27) | (0.11) | (0.26) | 0.32 | (1.13) |

| | | | | | | | |
|--------|--|--|---|---|---|---|---|
| XVII | Earnings per equity share (for discontinued operation): | | - | - | - | - | - |
| | (1) Basic | | | | | | |
| | (2) Diluted | | | | | | |
| XVII I | Earnings per equity share (for discontinued & continuing operations) | | - | - | - | - | - |
| | (1) Basic | | | | | | |
| | (2) Diluted | | | | | | |

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 13th November, 2018. 2. The Un-Audited Financial Results for the Quarter 2 and ended 30st September, 2018 have been prepared and reviewed by the Statutory Auditors in pursuance of Schedule III of Companies Act, 2013 3. The figures of the previous year/periods have been re-grouped/re-classified, whenever necessary, for the purpose of comparison. a. 4) The company operates in a single segment and the results pertain to a single segment. i.e., drug formulation only.

Reconciliation between net profit or loss reported in accordance with Indian GAAP (previous GAAP) and Ind AS for the quarter ended 30th September, 2018 and year ended 31 March 2018 is as follows:

| Particulars | Quarter Ended | | | Year ended | |
|---|---------------|-------------|-------------|------------|------------|
| | 30.09.2018 | 30.06.2018 | 30.09.2017 | 31.03.2017 | 31.03.2018 |
| | (Unaudited) | (Unaudited) | (Unaudited) | (Audited) | (Audited) |
| Net profit reported for the quarter earlier as per the previous Indian GAAP | (9.05) | (3.59) | (8.98) | 10.97 | (38.57) |
| Net profit for the period as per Ind AS | (9.05) | (3.59) | (8.98) | 10.97 | (38.57) |
| Other Comprehensive Income | - | - | - | - | - |
| Total Comprehensive Income for the period as per Ind AS | (9.05) | (3.59) | (8.98) | 10.97 | (38.57) |

For PHARMAIDS PHARMACEUTICALS LIMITED

Place : Hyderabad

Date : 13-11-2018

Chiranjeev
MANAGING DIRECTOR



Name of the Company **PHARMAIDS PHARMACEUTICALS LIMITED**
Balance Sheet as at 30st September,2018

(Rs in Lakhs)

| | Note No. | Figures as at the end of 30.09.2018 | Figures as at the end of 31.03.2018 |
|---|----------|-------------------------------------|-------------------------------------|
| Particulars | | | |
| 1 | 2 | 3 | 4 |
| 1 ASSETS | | | |
| Non-current assets | | | |
| (a) Property, Plant and Equipment | | 0.35 | 0.20 |
| (b) Capital work-in-progress | | - | - |
| (c) Investment Property | | - | - |
| (d) Goodwill | | - | - |
| (e) Other Intangible assets | | - | - |
| (f) Intangible assets under development | | - | - |
| (g) Biological Assets other than bearer plants | | - | - |
| (h) Financial Assets | | | |
| (i) Investments | | - | - |
| (ii) Trade receivables | | - | - |
| (iii) Loans | | - | - |
| (iv) Others (to be specified) | | - | - |
| (i) Deferred tax assets (net) | | | 0.03 |
| (j) Other non-current assets | | 45.70 | 51.50 |
| 2 Current assets | | | |
| (a) Inventories | | - | - |
| (b) Financial Assets | | | |
| (i) Investments | | | |
| (ii) Trade receivables | | 61.39 | 52.26 |
| (iii) Cash and cash equivalents | | 3.46 | 7.57 |
| (iv) Bank balances other than (iii) above | | 7.55 | 13.72 |
| (v) Loans | | | |
| (vi) Others (to be specified) | | | |
| (c) Current Tax Assets (Net) | | | |
| (d) Other current assets | | | |
| Total Assets | | 118.45 | 125.28 |
| EQUITY AND LIABILITIES Equity | | | |
| (a) Equity Share capital | | 336.31 | 336.31 |
| (b) Other Equity | | (244.74) | (235.69) |
| LIABILITIES | | | |
| 1 Non-current liabilities | | | |
| (a) Financial Liabilities | | | |
| (i) Borrowings | | 2.52 | 2.52 |
| (ii) Trade payables | | | |
| (iii) Other financial liabilities (other than those specified in item (b), to be specified) | | | |
| (b) Provisions | | | |
| (c) Deferred tax liabilities (Net) | | | |
| (d) Other non-current liabilities | | | |
| 2 Current liabilities | | | |
| (a) Financial Liabilities | | | |
| (i) Borrowings | | 2.78 | 2.78 |
| (ii) Trade payables | | 18.93 | 18.05 |
| (iii) Other financial liabilities (other than those specified in item (c)) | | | |
| (b) Other current liabilities | | 2.65 | 1.32 |
| (c) Provisions | | | |
| (d) Current Tax Liabilities (Net) | | | |
| Total Equity and Liabilities | | 118.45 | 125.28 |

21 Pharmaids Pharmaceuticals Ltd.

Ganesh Kumar

Managing Director